Serum Soluble ST2 and Plaque Vulnerability in Patients With Acute Coronary Syndrome

Elevated Serum Soluble ST2 Level is Associated With Increased Plaque Vulnerability in Patients With Non-ST Elevation Acute Coronary Syndrome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04797819

Enrollment

120

Registered

2021-03-15

Start date

2019-01-01

Completion date

2019-12-31

Last updated

2021-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Keywords

soluble ST2, plaque vulnerability

Brief summary

This study aimed to assess the association between serum sST2 level and plaque vulnerability in ACS patients. It is hypothesized that serum sST2 level may be related to plaque components and closely associated with plaque vulnerability.

Detailed description

Serum soluble suppression of tumorigenicity-2 (sST2) has emerged as a novel biomarker of atherosclerotic disease. This study aimed to investigate whether elevated serum sST2 level is related to coronary plaque components detected on coronary computed tomography angiography (CCTA) and plaque vulnerability in non-ST elevation acute coronary syndromes (ACS) patients. 167 lesions in 120 non-ST elevation ACS patients were prospectively enrolled and evaluated by CCTA in this study. Blood were taken from antecubital vein during patient's hospitalization for angiography. Serum sST2 level was measured by commerical ELISA kits (Presage ST2 Assay Kit, Critical Diagnostics). CCTA were performed using a 320-slice CT scanner (Aquilion ONE, Toshiba Medical Systems, Otawara, Japan). Coronary plaque components were analyzed cross each of the lesions using commercialized software package (QAngio CT, Medis, The Netherlands).

Interventions

DIAGNOSTIC_TESTCoronary plaque components

Coronary plaque components were detected by CCTA method

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Inclusion criteria

1. Clinical diagnosis of non-ST-elevation ACS 1. Non-ST-elevation myocardial infarction 2. Unstable angina 2. Age from 18 to 75 years 3. Underwent CCTA

Exclusion criteria

1. Patients needed an immediate (\< 2 h) or early invasive strategy (\< 24 h) according to guidelines: 1. Haemodynamic instability 2. Cardiogenic shock 3. Life-threatening arrhythmias or cardiac arrest 4. Mechanical complication 5. Acute heart failure 6. Dynamic ST or T wave changes 7. GRACE score \> 140 2. Patients with previous history of: 1. Coronary artery bypass graft surgery or percutaneous coronary intervention (PCI) 2. Immune system disorder 3. Tumor 4. Acute/chronic infection 5. Statin use within 3 months 6. Atrial fibrillation 7. End-stage renal failure 8. Iodine-containing contrast allergy 3. Patients with no significant (≥ 50%) stenosis on major epicardial vessels after CCTA performance 4. Patients refused subsequent angiography after CCTA performance 5. Patients with total obstruction on major epicardial vessel 6. Patients with insufficient image quality for QAngioCT analysis

Design outcomes

Primary

Measure	Time frame	Description
Distribution of plaque components by QAngioCT	Procedure (Coronary CTA )	Hounsfield unit (HU) -30 to 75 for necrotic core, HU 76-130 for fibrous fatty, HU 131-350 for fibrous tissue, and HU over 351 for dense calcium.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026